Article
PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 10 Oct 2014
Loibl Sibylle, von Minckwitz Gunter, Schneeweiss Andreas, Paepke Stefan, Lehmann Annika, Rezai Mahdi, Zahm Dirk M, Sinn Peter, Khandan Fariba, Eidtmann Holger, Dohnal Karel, Heinrichs Clemens, Huober Jens, Pfitzner Berit, Fasching Peter A, Andre Fabrice, Lindner Judith L, Sotiriou Christos, Dykgers August, Guo Sanxing, Gade Stephan, Nekljudova Valentina, Loi Sherene, Untch Michael, Denkert Carsten
Abstract excerpt
PURPOSE: Phosphatidylinositol 3-kinase (PI3K)/AKT pathway aberrations are common in breast cancer, with mutations in PIK3CA being the most common. This study investigated the association between PIK3CA genotype and pathologic complete response (pCR) rates in human epidermal growth factor receptor 2 (HER2)-positive breast cancer treated with either dual or single anti-HER2 treatment in addition to neoadjuvant...
Topics
Join the communities discussing this publication.